When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Generalized anxiety disorder

Última revisión: 16 Aug 2025
Última actualización: 29 May 2024

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • excessive worry for at least 6 months
  • anxiety not confined to another mental health disorder
  • anxiety not due to medication or substance
  • muscle tension
  • sleep disturbance
  • fatigue
  • restlessness
  • irritability
  • poor concentration
Todos los datos

Otros factores de diagnóstico

  • headache
  • sweating
  • dizziness
  • gastrointestinal symptoms
  • muscle aches
  • increased heart rate
  • shortness of breath
  • trembling
  • exaggerated startle response
  • chest pain
Todos los datos

Factores de riesgo

  • family history of anxiety
  • physical or emotional stress
  • history of physical, sexual, or emotional trauma
  • other anxiety disorder
  • chronic physical health condition
  • female sex
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • clinical diagnosis
Todos los datos

Pruebas diagnósticas que deben considerarse

  • thyroid function tests
  • urine drug screen
  • 24-hour urine for catecholamines, metanephrines, normetanephrines, and creatinine
  • pulmonary function tests
  • ECG
Todos los datos

Algoritmo de tratamiento

En curso

anxiety symptoms meeting DSM-5-TR criteria

anxiety symptoms not meeting DSM-5-TR criteria

Colaboradores

Autores

Philip John Cowen, MD, FRCPsych, FMedSci

Professor of Psychopharmacology

Department of Psychiatry

University of Oxford

Oxford

UK

Divulgaciones

PJC declares that he has no competing interests.

Agradecimientos

Professor Philip John Cowen would like to gratefully acknowledge Dr Christopher Gale, Dr Richard P. Swinson, Dr Elizabeth Hoge, and Dr Phebe Tucker, previous contributors to this topic.

Divulgaciones

CG is an author of the Royal Australian and New Zealand College of Psychiatrists clinical practice guideline on social phobia, panic disorder, and generalized anxiety disorder. Otago University has commercial and research relationships with multiple pharmaceutical companies. He is an author of a number of references cited in this topic. RPS has personally received royalties for articles published in UpToDate (Wolters Kluwer) and the Compendium of Therapeutic Choices, 2nd edition (Canadian Pharmacists Association). EH is an author of a number of references cited in this topic. PT has conducted research for GlaxoSmithKline, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Astra-Zeneca, Cephalon, Inc., and Ortho-McNeil. She has also consulted for Forest Pharmaceuticals and received honoraria from Pfizer, Inc. and Forest Pharmaceuticals.

Revisores por pares

Lori Davis, MD

Research Director

University of Alabama

School of Medicine Tuscaloosa Campus

College of Community Health Sciences

Tuscaloosa

AL

Divulgaciones

LD declares that she has no competing interests.

Arianna Di Florio, MD, PhD

Senior Clinical Lecturer

Division of Psychological Medicine and Clinical Neurosciences

Cardiff University

United Kingdom

Divulgaciones

ADF declares that she has no competing interests.

Elaine Lockhart, MB, BCH, BAO

Consultant in Paediatric Liaison Psychiatry

Royal Hospital for Children

Glasgow

United Kingdom

Divulgaciones

EL declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84. Resumen

Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018 Jun;212(6):333-8.Texto completo  Resumen

Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Diferenciales

    • Panic disorder
    • Social anxiety disorder
    • Obsessive-compulsive disorder
    Más Diferenciales
  • Guías de práctica clínica

    • Screening and diagnosis of mental health conditions during pregnancy and postpartum
    • Treatment and management of mental health conditions during pregnancy and postpartum
    Más Guías de práctica clínica
  • Folletos para el paciente

    Anxiety: what is it?

    Anxiety: what are the treatment options?

    Más Folletos para el paciente
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad